Brian Heinen
Family Medicine · Eunice, LANPI 1457362899
Payments from drug & device makers
Across 260 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$796
- AbbVie$771
- Pfizer$336
- Lilly USA, LLC$244
- Abbott$207
- Novo Nordisk$206
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,438100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,451 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 28 | $55,053 |
| JanuviaSitagliptin Phosphate | 112 | $43,647 |
| EliquisApixaban | 126 | $38,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $38,573 |
| XareltoRivaroxaban | 31 | $27,405 |
| JardianceEmpagliflozin | 48 | $24,860 |
| EntrestoSacubitril/Valsartan | 44 | $21,705 |
| OzempicSemaglutide | 20 | $19,550 |
| LinzessLinaclotide | 27 | $19,097 |
| TrulicityDulaglutide | 15 | $17,728 |
| FarxigaDapagliflozin Propanediol | 13 | $10,177 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,908 |
| BrilintaTicagrelor | 30 | $8,667 |
| Imatinib Mesylate | 11 | $6,990 |
| GemtesaVibegron | 26 | $6,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $796 | $52,43689 claims |
| PfizerEliquis | $336 | $38,817126 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $60 | $27,85764 claims |
| AbbVieLinzess, Combigan | $771 | $23,60148 claims |
| NovartisEntresto | $87 | $21,70544 claims |
| Novo NordiskOzempic, Levemir | $206 | $21,58637 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $113 | $20,79854 claims |
| Lilly USA, LLCTrulicity | $244 | $17,72815 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,641275 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Eunice
- David WareEunice$29K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.